| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.
|
Gastroenterology
|
2010
|
7.86
|
|
2
|
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.
|
Clin Infect Dis
|
2005
|
5.20
|
|
3
|
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study.
|
Clin Infect Dis
|
2011
|
4.31
|
|
4
|
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
|
Clin Infect Dis
|
2005
|
3.57
|
|
5
|
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
|
Arch Intern Med
|
2003
|
3.41
|
|
6
|
Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study.
|
J Acquir Immune Defic Syndr
|
2013
|
3.02
|
|
7
|
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
|
Clin Infect Dis
|
2011
|
2.98
|
|
8
|
Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission.
|
Clin Infect Dis
|
2006
|
2.93
|
|
9
|
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.
|
Liver Int
|
2011
|
2.77
|
|
10
|
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.
|
J Infect Dis
|
2005
|
2.58
|
|
11
|
CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
|
Clin Infect Dis
|
2008
|
2.35
|
|
12
|
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study.
|
Clin Infect Dis
|
2005
|
2.35
|
|
13
|
Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland.
|
J Infect Dis
|
2010
|
2.21
|
|
14
|
Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
|
Clin Infect Dis
|
2010
|
2.17
|
|
15
|
Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study.
|
Clin Infect Dis
|
2010
|
2.12
|
|
16
|
Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008.
|
Am J Psychiatry
|
2009
|
2.12
|
|
17
|
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
|
Arch Intern Med
|
2010
|
2.05
|
|
18
|
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic.
|
Clin Infect Dis
|
2012
|
2.04
|
|
19
|
Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.
|
Clin Infect Dis
|
2007
|
1.98
|
|
20
|
Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study.
|
J Acquir Immune Defic Syndr
|
2006
|
1.95
|
|
21
|
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population.
|
Lancet
|
2003
|
1.94
|
|
22
|
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
|
J Infect Dis
|
2005
|
1.93
|
|
23
|
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
|
Lancet
|
2006
|
1.91
|
|
24
|
All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population.
|
AIDS
|
2004
|
1.91
|
|
25
|
Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival.
|
AIDS
|
2003
|
1.87
|
|
26
|
The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV.
|
AIDS
|
2015
|
1.84
|
|
27
|
Stable virulence levels in the HIV epidemic of Switzerland over two decades.
|
AIDS
|
2006
|
1.81
|
|
28
|
Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.
|
Arch Intern Med
|
2007
|
1.80
|
|
29
|
Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study.
|
J Infect Dis
|
2008
|
1.76
|
|
30
|
Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study.
|
J Acquir Immune Defic Syndr
|
2010
|
1.75
|
|
31
|
Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study.
|
J Acquir Immune Defic Syndr
|
2003
|
1.70
|
|
32
|
Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication.
|
Eur J Immunol
|
2008
|
1.70
|
|
33
|
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.
|
Proc Natl Acad Sci U S A
|
2012
|
1.65
|
|
34
|
Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.
|
Clin Infect Dis
|
2011
|
1.64
|
|
35
|
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load.
|
PLoS Pathog
|
2010
|
1.63
|
|
36
|
The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study.
|
AIDS
|
2004
|
1.63
|
|
37
|
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.
|
AIDS
|
2002
|
1.63
|
|
38
|
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque.
|
J Clin Invest
|
2011
|
1.61
|
|
39
|
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2007
|
1.55
|
|
40
|
Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
|
Clin Infect Dis
|
2009
|
1.53
|
|
41
|
Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.
|
Gut
|
2010
|
1.53
|
|
42
|
Ocular toxoplasmosis during natalizumab treatment.
|
Neurology
|
2009
|
1.51
|
|
43
|
Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland.
|
Clin Infect Dis
|
2009
|
1.50
|
|
44
|
Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting.
|
Eur J Epidemiol
|
2004
|
1.50
|
|
45
|
Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection.
|
J Acquir Immune Defic Syndr
|
2010
|
1.49
|
|
46
|
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.
|
J Infect Dis
|
2010
|
1.45
|
|
47
|
Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
|
Antivir Ther
|
2011
|
1.44
|
|
48
|
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.
|
J Acquir Immune Defic Syndr
|
2011
|
1.44
|
|
49
|
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
|
Arch Intern Med
|
2003
|
1.44
|
|
50
|
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
|
AIDS
|
2012
|
1.42
|
|
51
|
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort.
|
AIDS
|
2002
|
1.41
|
|
52
|
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l.
|
AIDS
|
2002
|
1.38
|
|
53
|
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
|
Antivir Ther
|
2005
|
1.36
|
|
54
|
Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey.
|
J Clin Microbiol
|
2003
|
1.33
|
|
55
|
JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.
|
J Virol
|
2009
|
1.32
|
|
56
|
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2010
|
1.30
|
|
57
|
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.
|
Hepatology
|
2011
|
1.30
|
|
58
|
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2008
|
1.29
|
|
59
|
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
|
Pharmacogenet Genomics
|
2007
|
1.25
|
|
60
|
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.
|
PLoS One
|
2011
|
1.24
|
|
61
|
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control.
|
Elife
|
2013
|
1.19
|
|
62
|
Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.
|
Clin Infect Dis
|
2011
|
1.17
|
|
63
|
HIV transmission under highly active antiretroviral therapy.
|
Lancet
|
2008
|
1.17
|
|
64
|
Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification.
|
Antivir Ther
|
2007
|
1.14
|
|
65
|
Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.
|
Antivir Ther
|
2008
|
1.14
|
|
66
|
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.
|
Blood
|
2004
|
1.14
|
|
67
|
Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
|
AIDS
|
2008
|
1.13
|
|
68
|
Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy.
|
Antivir Ther
|
2007
|
1.12
|
|
69
|
Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study.
|
AIDS
|
2010
|
1.11
|
|
70
|
Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study.
|
Clin Infect Dis
|
2013
|
1.08
|
|
71
|
Epidemiology of methicillin-resistant Staphylococcus aureus: results of a nation-wide survey in Switzerland.
|
Swiss Med Wkly
|
2002
|
1.08
|
|
72
|
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.
|
J Acquir Immune Defic Syndr
|
2005
|
1.07
|
|
73
|
Ageing with HIV: medication use and risk for potential drug-drug interactions.
|
J Antimicrob Chemother
|
2011
|
1.04
|
|
74
|
HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis.
|
PLoS Genet
|
2013
|
1.04
|
|
75
|
Severe large bowel obstruction secondary to infection with Actinomyces israelii.
|
Scand J Infect Dis
|
2006
|
1.03
|
|
76
|
The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland.
|
J Infect Dis
|
2011
|
1.03
|
|
77
|
Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2009
|
1.03
|
|
78
|
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
|
Clin Infect Dis
|
2008
|
1.02
|
|
79
|
Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death.
|
AIDS
|
2011
|
1.02
|
|
80
|
Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.
|
PLoS One
|
2009
|
1.01
|
|
81
|
CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
|
Antivir Ther
|
2007
|
0.99
|
|
82
|
Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study.
|
Antivir Ther
|
2006
|
0.99
|
|
83
|
Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
|
Circ Cardiovasc Genet
|
2009
|
0.99
|
|
84
|
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
|
J Infect Dis
|
2002
|
0.99
|
|
85
|
Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
|
Arch Intern Med
|
2012
|
0.98
|
|
86
|
Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study.
|
J Infect Dis
|
2013
|
0.97
|
|
87
|
Infection of the central nervous system caused by varicella zoster virus reactivation: a retrospective case series study.
|
Int J Infect Dis
|
2013
|
0.96
|
|
88
|
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection.
|
J Infect Dis
|
2013
|
0.96
|
|
89
|
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality.
|
AIDS
|
2015
|
0.95
|
|
90
|
Frequency of gynecologic follow-up and cervical cancer screening in the Swiss HIV cohort study.
|
J Acquir Immune Defic Syndr
|
2006
|
0.95
|
|
91
|
Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study.
|
PLoS One
|
2013
|
0.95
|
|
92
|
Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals.
|
Clin Infect Dis
|
2010
|
0.94
|
|
93
|
Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study.
|
BMJ
|
2004
|
0.93
|
|
94
|
Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.
|
Antivir Ther
|
2009
|
0.92
|
|
95
|
A randomized crossover study to compare efavirenz and etravirine treatment.
|
AIDS
|
2011
|
0.91
|
|
96
|
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study.
|
J Acquir Immune Defic Syndr
|
2012
|
0.91
|
|
97
|
Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes.
|
PLoS One
|
2012
|
0.91
|
|
98
|
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
|
Antivir Ther
|
2007
|
0.91
|
|
99
|
Overall burden of healthcare-associated infections among surgical patients. Results of a national study.
|
Ann Surg
|
2011
|
0.91
|
|
100
|
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
|
AIDS
|
2011
|
0.90
|
|
101
|
Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
|
J Acquir Immune Defic Syndr
|
2015
|
0.87
|
|
102
|
Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study.
|
AIDS
|
2004
|
0.87
|
|
103
|
Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection.
|
BMC Infect Dis
|
2011
|
0.87
|
|
104
|
Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study.
|
AIDS Res Hum Retroviruses
|
2004
|
0.87
|
|
105
|
Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.
|
PLoS One
|
2012
|
0.87
|
|
106
|
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
|
PLoS One
|
2012
|
0.86
|
|
107
|
The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients.
|
AIDS
|
2014
|
0.86
|
|
108
|
A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.
|
PLoS One
|
2011
|
0.86
|
|
109
|
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
|
Pharmacogenet Genomics
|
2013
|
0.85
|
|
110
|
Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide.
|
J Infect Dis
|
2014
|
0.85
|
|
111
|
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.
|
PLoS One
|
2012
|
0.85
|
|
112
|
Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals.
|
Antivir Ther
|
2013
|
0.85
|
|
113
|
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART.
|
AIDS
|
2003
|
0.85
|
|
114
|
Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.
|
AIDS Res Hum Retroviruses
|
2010
|
0.83
|
|
115
|
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
|
AIDS
|
2014
|
0.83
|
|
116
|
Malignant otitis externa due to Aspergillus niger.
|
Scand J Infect Dis
|
2003
|
0.82
|
|
117
|
High proportion of healthcare-associated urinary tract infection in the absence of prior exposure to urinary catheter: a cross-sectional study.
|
Antimicrob Resist Infect Control
|
2013
|
0.82
|
|
118
|
Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
|
Antivir Ther
|
2005
|
0.81
|
|
119
|
Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study.
|
Antivir Ther
|
2014
|
0.81
|
|
120
|
CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART.
|
Medicine (Baltimore)
|
2016
|
0.81
|
|
121
|
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
|
AIDS
|
2007
|
0.80
|
|
122
|
Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.
|
Antivir Ther
|
2004
|
0.80
|
|
123
|
Evaluation of prescription practices of antibiotics in a medium-sized Swiss hospital.
|
Swiss Med Wkly
|
2005
|
0.80
|
|
124
|
Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy.
|
Antivir Ther
|
2010
|
0.80
|
|
125
|
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.
|
AIDS
|
2004
|
0.79
|
|
126
|
Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.
|
Swiss Med Wkly
|
2010
|
0.79
|
|
127
|
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS).
|
J Acquir Immune Defic Syndr
|
2013
|
0.79
|
|
128
|
Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.
|
J Transl Med
|
2011
|
0.78
|
|
129
|
Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study.
|
J Acquir Immune Defic Syndr
|
2012
|
0.78
|
|
130
|
Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia.
|
Clin Infect Dis
|
2010
|
0.78
|
|
131
|
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy.
|
J Infect Dis
|
2011
|
0.78
|
|
132
|
Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy.
|
AIDS
|
2005
|
0.78
|
|
133
|
The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study.
|
Antivir Ther
|
2012
|
0.77
|
|
134
|
Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.
|
J Clin Epidemiol
|
2008
|
0.77
|
|
135
|
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.
|
PLoS Comput Biol
|
2013
|
0.77
|
|
136
|
Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic.
|
J Acquir Immune Defic Syndr
|
2011
|
0.76
|
|
137
|
The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events.
|
J Acquir Immune Defic Syndr
|
2016
|
0.76
|
|
138
|
Granulomatous hepatitis after intravesical bacillus Calmette-Guérin treatment.
|
Scand J Infect Dis
|
2010
|
0.75
|
|
139
|
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals.
|
Medicine (Baltimore)
|
2017
|
0.75
|
|
140
|
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population.
|
AIDS
|
2016
|
0.75
|
|
141
|
Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis.
|
Clin Infect Dis
|
2003
|
0.75
|
|
142
|
Trichinellosis in immigrants in Switzerland.
|
J Travel Med
|
2012
|
0.75
|
|
143
|
Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals.
|
HIV Clin Trials
|
2009
|
0.75
|
|
144
|
Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study.
|
HIV Clin Trials
|
2007
|
0.75
|
|
145
|
Telaprevir-induced renal impairment: three clinical cases and a review of the literature.
|
Infect Dis (Lond)
|
2015
|
0.75
|
|
146
|
Adverse events of raltegravir and dolutegravir: a prospective analysis of 4,041 HIV-infected individuals from the Swiss HIV Cohort Study.
|
AIDS
|
2017
|
0.75
|
|
147
|
Intractable Neck Pain in an Oncologic Palliative Care Setting: Is Cancer Always the Answer?
|
J Pain Palliat Care Pharmacother
|
2017
|
0.75
|
|
148
|
Human papillomavirus antibody response following HAART initiation among MSM.
|
AIDS
|
2017
|
0.75
|